LambdaVision to Study Light-Activated Proteins on NASA’s Upcoming Flight to International Space Station30 Sep 2020, 10:28 UTC
FARMINGTON, Conn. (LambdaVision PR) — LambdaVision, an innovative biotech developing a treatment to help patients regain sight, will launch their artificial retina technology with engineering partner Space Tango on Northrop Grumman’s 14th Commercial Resupply Services Mission for NASA (NG-14) to the International Space Station (ISS) U.S. National Laboratory.
Scheduled to launch on September 30th at 2:26 UTC (10:26 p.m. ET), NG-14 is the first of a series of NASA flights to the ISS in low-Earth orbit (LEO) focused on developing the on-orbit production of LambdaVision’s artificial retina.
LambdaVision’s research on the ISS focuses on exploring the benefits of microgravity for producing its artificial retina, and expands on research being conducted on Earth and previous efforts on the ISS. Funding for this research effort was made possible by two awards from NASA that underscore the technology readiness and commercial potential of the product, while supporting NASA’s strategic plan to leverage microgravity for a broad range of biomedical and technology applications.
“As we continue to grow the low-Earth orbit economy, missions such as this lend great insight into the potential uses of microgravity,” said Space Tango Chief Executive Officer and Co-Founder Twyman Clements. “Space Tango is excited for our continued ...